Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.
Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, Rama N, Chen M, Pickford E, Agarwal R, Blagden S, Carme S, Salinas C, Madison S, Krachey E, Santiago-Walker A, Smith DA, Morris SR, Stronach EA, Gabra H. Gungor H, et al. Among authors: gabra h. J Nucl Med. 2015 Dec;56(12):1828-35. doi: 10.2967/jnumed.115.156505. Epub 2015 Oct 1. J Nucl Med. 2015. PMID: 26429956 Free article. Clinical Trial.
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
Cheraghchi-Bashi A, Parker CA, Curry E, Salazar JF, Gungor H, Saleem A, Cunnea P, Rama N, Salinas C, Mills GB, Morris SR, Kumar R, Gabra H, Stronach EA. Cheraghchi-Bashi A, et al. Among authors: gabra h. Oncotarget. 2015 Dec 8;6(39):41736-49. doi: 10.18632/oncotarget.6153. Oncotarget. 2015. PMID: 26497682 Free PMC article. Clinical Trial.
Promising molecular targets in ovarian cancer.
Blagden S, Gabra H. Blagden S, et al. Among authors: gabra h. Curr Opin Oncol. 2009 Sep;21(5):412-9. doi: 10.1097/CCO.0b013e32832eab1f. Curr Opin Oncol. 2009. PMID: 19553815 Review.
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
Blagden SP, Hamilton AL, Mileshkin L, Wong S, Michael A, Hall M, Goh JC, Lisyanskaya AS, DeSilvio M, Frangou E, Stronach EA, Gopalakrishna P, Meniawy TM, Gabra H. Blagden SP, et al. Among authors: gabra h. Clin Cancer Res. 2019 Mar 1;25(5):1472-1478. doi: 10.1158/1078-0432.CCR-18-2277. Epub 2018 Dec 18. Clin Cancer Res. 2019. PMID: 30563934 Free article. Clinical Trial.
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H. Stronach EA, et al. Among authors: gabra h. Cancer Res. 2011 Jul 1;71(13):4412-22. doi: 10.1158/0008-5472.CAN-10-4111. Epub 2011 May 13. Cancer Res. 2011. PMID: 21571862 Free PMC article.
217 results